^
Association details:
| Biomarker: | HER-2 underexpression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Aidixi (disitamab vedotin) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) + lemzoparlimab (ABBV-IMAB-TJC4) (CD47 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
859 Combination of HER2 ADC and lemzoparlimab elicits enhanced efficacy in both HER2 high-and low-expressing breast and gastric cancers
Published date:
11/08/2022
Excerpt:
In combination with lemzoparlimab in vitro, RC48-mediated cytotoxicity against both BT-474 and MCF-7 cells was enhanced, while the increase in cytotoxicity was more prominent in HER2-low MCF-7 cells than HER2-high BT474 cells....The synergistic efficacy by combination treatment was more pronounced in tumor with HER2-low expression than that with HER2-high expression.
DOI:
http://dx.doi.org/10.1136/jitc-2022-SITC2022.0859
